Nipro PharmaPackaging announced today that it launched new D2F (direct-to-fill) glass vials powered by Stevanato Group technology. The vials feature Stevanato’s EZ-fill technology to offer a high-quality, ready-to-use (RTU) solution. Nipro designed the vials to meet the rigorous standards and increasing requirements of the pharmaceutical industry. D2F vials are washed, depyrogenated, packaged in nest and…
BD partners with ten23 health on prefilled syringe manufacturing
BD (NYSE:BDX) announced today that it entered into a collaboration with ten23 health to develop a new way to track prefillable syringes (PFS). ten23 health, a Swiss CDMO, offers drug development, filling and device assembly expertise to contribute to the product offering. It recently entered into a production collaboration with on-body drug delivery device maker…
SK Pharmteco invests $260M to expand small molecule, peptide production
SK Pharmteco announced that it expanded its small molecule and peptide production capabilities with a $260 million investment. The Rancho Cordova, California-based CDMO plans to construct a new state-of-the-art facility in Sejong, South Korea. It expects to begin operations at the new plant — the company’s fifth in South Korea — in late 2026. The…
Eli Lilly opens new $4.5B pharmaceutical manufacturing plant in Indiana
Eli Lilly (NYSE:LLY) announced today that it made a $4.5 billion investment to create the Lilly Medicine Foundry in Indiana. The new center offers capabilities for advanced manufacturing and drug development. Lilly expects to gain new ways to produce medicines while also scaling up manufacturing of medicines for clinical trials. Its first-of-its-kind facility combines research…
PCI Pharma Services makes $365M investment in drug delivery device manufacturing
PCI Pharma Services announced that it’s investing more than $365 million in infrastructure to support assembly and packaging efforts. The investment supports the clinical- and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. PCI Pharma plans to put its investment toward new and…
Curium to open new cancer isotope production facility in The Netherlands
Curium announced today that it opened a new facility in Petten, The Netherlands, to produce non-carrier added lutetium-177 (Lu-177). The Paris-based company expanded its capacity to meet the growing global demand for Lu-177 for the treatment of cancer patients. Using in-licensed technology from Turkey-based Eczacıbaşı-Monrol, the facility will initially include two production lines. Curium also…
Wheeler Bio licenses antibody production tech from ATUM
Wheeler Bio announced today that it expanded its capabilities through the licensing of ATUM’s miFuc platform. ATUM designed miFuc for the expression of recombinant proteins containing afucosylated glycans. The technology supports the development of antibodies with a significant reduction in fucosylation without affecting product titer, cellular growth rates or incurring global glycan liabilities. ATUM’s proprietary…
BD launches new prefillable syringe, expands platform capacity
BD (NYSE:BDX) announced today that it launched its Neopak XtraFlow glass prefillable syringe and expanded capacity for the platform. The company said the launch and expansion aim to serve the growing market for biologic therapies. Neopak glass prefillable syringes address key development needs for biologic drugs, BD said in a news release. The syringes have…
Biomanufacturing company Cellevate raises $3.6M to enter into global commercialization
Cellevate announced today that it closed a second seed round worth approximately $3.6 million to support its biomanufacturing technology. Industrifonden led the round in syndication with the European Innovation Council Fund (EIC Fund). The funding, combined with the first seed round last October, brings the company’s total funding to approximately 7.3 million. Lund, Sweden-based Cellevate…
Sanofi to open new Beyfortus manufacturing line in U.S. ahead of RSV season
Sanofi announced today that it’s shipping Beyfortus injection doses to the U.S. to ensure availability ahead of respiratory syncytial virus (RSV) season. The company shipped 50mg and 100mg injection doses of Beyfortus (nirsevimab-alip) to private healthcare providers and the Centers for Disease Control and Prevention for its Vaccines for Children program. Sanofi expects the U.S.…